Literature DB >> 35760857

A clinically relevant model of focal embolic cerebral ischemia by thrombus and thrombolysis in rhesus monkeys.

Di Wu1,2, Jian Chen1,3, Longfei Wu1, Hangil Lee4, Jingfei Shi1, Mo Zhang5, Yanhui Ma6, Xiaoduo He1, Zixin Zhu1, Feng Yan1, Chuanjie Wu1, Yunxia Duan1, Yongjuan Fu7, Sijie Li2, Xinglong Zhi3, Xuxiang Zhang8, Shengli Li9, Yuchuan Ding4, Xunming Ji10,11,12.   

Abstract

Over decades of research into the treatment of stroke, nearly all attempts to translate experimental treatments from discovery in cells and rodents to use in humans have failed. The prevailing belief is that it might be necessary to pretest pharmacological neuroprotection in higher-order brains, especially those of nonhuman primates (NHPs). Over the past few years, chemical thrombolysis and mechanical thrombectomy have been established as the standard of care for ischemic stroke in patients. The spotlight is now shifting towards emphasizing both focal ischemia and subsequent reperfusion in developing a clinically relevant stroke model in NHPs. This protocol describes an embolic model of middle cerebral artery occlusion in adult rhesus monkeys. An autologous clot is combined with a microcatheter or microwire through endovascular procedures, and reperfusion is achieved through local intra-artery thrombolysis with tissue plasminogen activator. These NHP models formed relatively stable infarct sizes, delivered predictable reperfusion and survival outcomes, and recapitulated key characteristics of patients with ischemic stroke as observed on MRI images and behavioral assays. Importantly, treated animals could survive 30 d after the surgery for post-stroke neurologic deficit analyses. Thus far, this model has been used in several translational studies. Here we describe in detail the teamwork necessary for developing stroke models of NHPs, including the preoperation preparations, endovascular surgery, postoperation management and histopathological analysis. The model can be established by the following procedures over a 45-d period, including preparation steps (14 d), endovascular operation (1 d) and evaluation steps (30 d).
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35760857     DOI: 10.1038/s41596-022-00707-5

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   17.021


  91 in total

1.  NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.

Authors:  J W Marshall; K J Duffin; A R Green; R M Ridley
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

Review 2.  A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.

Authors:  Ligen Shi; Marcelo Rocha; Rehana K Leak; Jingyan Zhao; Tarun N Bhatia; Hongfeng Mu; Zhishuo Wei; Fang Yu; Susan L Weiner; Feifei Ma; Tudor G Jovin; Jun Chen
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-07       Impact factor: 6.200

3.  Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.

Authors:  Douglas J Cook; Lucy Teves; Michael Tymianski
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

4.  Analysis of glucose metabolism in cynomolgus monkeys during aging.

Authors:  Di Wu; Feng Yue; Chunlin Zou; Piu Chan; Y Alex Zhang
Journal:  Biogerontology       Date:  2011-11-05       Impact factor: 4.277

5.  Thresholds in cerebral ischemia - the ischemic penumbra.

Authors:  J Astrup; B K Siesjö; L Symon
Journal:  Stroke       Date:  1981 Nov-Dec       Impact factor: 7.914

6.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.

Authors:  Mayank Goyal; Bijoy K Menon; Wim H van Zwam; Diederik W J Dippel; Peter J Mitchell; Andrew M Demchuk; Antoni Dávalos; Charles B L M Majoie; Aad van der Lugt; Maria A de Miquel; Geoffrey A Donnan; Yvo B W E M Roos; Alain Bonafe; Reza Jahan; Hans-Christoph Diener; Lucie A van den Berg; Elad I Levy; Olvert A Berkhemer; Vitor M Pereira; Jeremy Rempel; Mònica Millán; Stephen M Davis; Daniel Roy; John Thornton; Luis San Román; Marc Ribó; Debbie Beumer; Bruce Stouch; Scott Brown; Bruce C V Campbell; Robert J van Oostenbrugge; Jeffrey L Saver; Michael D Hill; Tudor G Jovin
Journal:  Lancet       Date:  2016-02-18       Impact factor: 79.321

7.  1,026 experimental treatments in acute stroke.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; Laura L Horky; Bart H van der Worp; David W Howells
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

Review 8.  Assessing the efficacy of endovascular therapy in stroke treatments: updates from the new generation of trials.

Authors:  Gregory B Walker; Ashutosh P Jadhav; Tudor G Jovin
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-09-04

Review 9.  Update of the stroke therapy academic industry roundtable preclinical recommendations.

Authors:  Marc Fisher; Giora Feuerstein; David W Howells; Patricia D Hurn; Thomas A Kent; Sean I Savitz; Eng H Lo
Journal:  Stroke       Date:  2009-02-26       Impact factor: 7.914

Review 10.  Ischemic stroke: experimental models and reality.

Authors:  Clemens J Sommer
Journal:  Acta Neuropathol       Date:  2017-01-07       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.